Full Press Release Details
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate.
ALT
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Key Takeaway: Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight